Download full-text PDF |
Source |
---|
Front Immunol
June 2024
Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
Introduction: Complement factor H (FH) is a major regulator of the complement alternative pathway, its mutations predispose to an uncontrolled activation in the kidney and on blood cells and to secondary C3 deficiency. Plasma exchange has been used to correct for FH deficiency and although the therapeutic potential of purified FH has been suggested by experiments in animal models, a clinical approved FH concentrate is not yet available. We aimed to develop a purification process of FH from a waste fraction rather than whole plasma allowing a more efficient and ethical use of blood and plasma donations.
View Article and Find Full Text PDFBackground: There is little published information on the natural history and the treatment of immune complex membrano-proliferative glomerulonephritis (IC-MPGN) of unknown cause in the transplanted kidney.
Materials And Methods: From 01/2004 to 12/2018, 41 patients had the diagnosis of post-transplant idiopathic IC-MPGN and were included in the study.
Results: The mean age of the cohort at the time of transplant was 50 ± 13 years.
BMC Nephrol
December 2022
Department of Nephrology, Vito Fazzi Hospital, Lecce, Italy.
BMC Nephrol
February 2022
Department of Nephrology, Aix-Marseille Univ, Hôpital de la Conception, AP-HM, 147 Bd Baille, 13005, Marseille, France.
Nephrol Ther
April 2022
Department of internal medicine : Multi-organic diseases, Local Referral Center for Auto-immune Diseases, Saint-Eloi Hospital, Montpellier University Hospital, 34295 Montpellier, France.
Systemic mastocytosis is characterised by tissular infiltration and a cytokine storm due to mast cells excessive proliferation and activation. Herein, we report an extraordinary case of AH1N1 influenza post-viral glomerulonephritis occurring in the course of an aggressive systemic mastocytosis with an associated hematological neoplasm. Because of a multisystemic involvement including the liver and lungs, we treated mastocytosis with midostaurin (multiple inhibitor of kinase protein), anti H1/H2 blockers and dexamethasone as first line treatment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!